The authors report their experience with 10 patients subjected to chemotherapy for urinary cancer. The decision to prolong therapy sprang from the persistent efficacy of the same and the will to live of the actual patients, while respecting the classical moral principles of bioethics.
YagodaA.: Chemotherapy of advanced urothelial tract cancer: Memorial Sloan-Kettering cancer center experience. New trend in bladder cancer chemotherapy. Cannes 22–25 October 1987.
2.
SternbergC., YagodaA., ScherH.J., WatsonR.C., GellerN., HerrH. W., MorsM.J., SoganiP.C., VaughanE.D., BanderN., LinS., PenesbergD., FairW.R., WhitemoreW.F.jr.: M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer, 64: 2448, 1989.
3.
ChengD.L., UngerP., ForscherC.A., FindE.M.: Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicina and cisplatino therapy. J. Urol., 153; 417–4191995.
4.
StockleM., MeyenburgW., WellekS., VogsG.E., RossmannM., GertenbachU., ThuroffJ.W., HuberC., HohenfellnerR.: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy rivisited: longterm results of a controlled prospective study and further clinical experience. J. Urology, 153: 47–52, 1995.
5.
DreicerR., RothB.J., EinhornL.H., SmithJ.A., PropertK., LoehererP.J.: Vinblastine, ipofamide and gallium nitrate (V1G) in advanced carcinoma of the urothelium: a phase II trial of the eastern cooperative oncology group. J. Urol., 153; 486A–959, 1995.
6.
De LaPena J., Martinez-PineiroJ. A., CisnerosJ., LeonJ., BenitezM., MoraH.: M-VAC chemotherapy in disseminated bladder cancer. New trend in bladder cancer chemotherapy. Cannes, 22–25 October 1987.
7.
Martinez-PineiroJ. A.: Valutazione critica della terapia neo-audiuvante e audiuvante della terapia del carcinoma della vescica. Atti V° Corso Internazionale di Aggiornamento in Urologia. Copanello, 166–169, 1994.
8.
KamizuroM., IkermotoS., AsaiY., MatudaJ., TeradaT., KishimotoT.: Combination therapy with cyclofosfamide and OK-432 auguents immunity against murine bladder tumours in nice. J. Urol., 151: 517A, 1994.
9.
PortigliattiBarbos M.: Ai limiti della scienza legale per i medici. Il Medico d'Italia.11, 7/12/1995.
10.
SternbergC., ArenaM., CalabresiF.: Neo adjuvant MVAC for infiltrating transitional cell carcinoma of the urothelium. Cancer, 72: 1975–82, 1993.
AnzaniA.: Il carcinoma infiltrante della vescica: considerazioni etiche. Forum, 4 (3): 2–31, 1994.
13.
Codice di Deontologia Medica. Consiglio Nazionale della FNOMCEO, 24–25 giugno 1995.
14.
LogothetisC.J., DexusF.H., SellaA., AmatoR.J., KilboumR.G., FinnL., GuttermanJ.U.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J. Clin. Onc., 8: 1050–1055, 1990.
15.
MooreM.J., IscoeN., TannockI.F.: A phase II study of methotrexate, vinblastine, doxorubicina and cisplatino plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J. Urol., 150: 1131–1134, 1993.
16.
StoterG., SplinterT.A.W., ChildJ.A., FossaS.D., DenisL., Van OosteromA.T., De PlawM., SylvesterR.: E.O.R.T.C. genito-urinary group: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol., 137: 663, 1987.
17.
Giovanni Paolo II: Varcare la soglia della speranza. Mondadori Ed., 272, 1994.
